MNG1140
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.471
- ALLOGRAFT_REJECTION+0.321
- IL6_JAK_STAT3_SIGNALING+0.305
- COAGULATION+0.304
- OXIDATIVE_PHOSPHORYLATION+0.301
- ANGIOGENESIS+0.297
- INTERFERON_GAMMA_RESPONSE+0.291
- MYC_TARGETS_V2+0.250
- INFLAMMATORY_RESPONSE+0.248
- APICAL_SURFACE+0.191
Top 10 suppressed
- NOTCH_SIGNALING-0.413
- ANDROGEN_RESPONSE-0.343
- PEROXISOME-0.338
- TGF_BETA_SIGNALING-0.315
- UV_RESPONSE_DN-0.310
- PROTEIN_SECRETION-0.259
- BILE_ACID_METABOLISM-0.240
- HEME_METABOLISM-0.233
- MITOTIC_SPINDLE-0.213
- CHOLESTEROL_HOMEOSTASIS-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016958 | — | — | 0.769 |
| 2 | MNG1270 | — | — | 0.738 |
| 3 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.731 |
| 4 | TCGA-95-7944-01A-11R-2187-07 | — | cohortA1 | 0.724 |
| 5 | TCGA-AC-A2QJ-01A-12R-A19W-07 | — | A | 0.721 |
| 6 | 0ec02d90-7ccb-476e-a8bb-9a9c8f158dee | — | — | 0.720 |
| 7 | SRR33346959 | — | — | 0.712 |
| 8 | R61 | — | — | 0.706 |
| 9 | R50 | — | — | 0.705 |
| 10 | 7e314d4a-7158-4d60-a431-013abe183071 | — | — | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.471 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.321 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.305 | Inavolisib | — uncovered |
| COAGULATION | 0.304 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.301 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.297 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.291 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.248 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.191 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.177 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.168 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.156 | Inavolisib | — uncovered |
| COMPLEMENT | 0.155 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.132 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.107 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.104 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.077 | Idelalisib | — uncovered |
| APOPTOSIS | 0.064 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.064 | Cobimetinib | — uncovered |